MURAL - Maynooth University Research Archive Library

    Clenbuterol activates the central IL-1 system via the b2-adrenoceptor without provoking inflammatory response related behaviours in rats

    Ryan, Karen M. and Griffin, Éadaoin W. and Ryan, Katie J. and Tanveer, Riffat and Vanattou-Saifoudine, Natacha and McNamee, Eóin N. and Fallon, Emer and Heffernan, Sheena and Harkin, Andrew and Connor, Thomas J. (2016) Clenbuterol activates the central IL-1 system via the b2-adrenoceptor without provoking inflammatory response related behaviours in rats. Brain, Behavior, and Immunity, 56. pp. 114-129. ISSN 0889-1591

    Download (3MB) | Preview

    Share your research

    Twitter Facebook LinkedIn GooglePlus Email more...

    Add this article to your Mendeley library


    The long-acting, highly lipophilic, b2-adrenoceptor agonist clenbuterol may represent a suitable therapeutic agent for the treatment of neuroinflammation as it drives an anti-inflammatory response within the CNS. However, clenbuterol is also known to increase the expression of IL-1b in the brain, a potent neuromodulator that plays a role in provoking sickness related symptoms including anxiety and depression-related behaviours. Here we demonstrate that, compared to the immunological stimulus lipopolysaccharide (LPS, 250 lg/kg), clenbuterol (0.5 mg/kg) selectively up-regulates expression of the central IL-1 system resulting in a mild stress-like response which is accompanied by a reduction in locomotor activity and food consumption in rats. We provide further evidence that clenbuterol-induced activation of the central IL-1 system occurs in a controlled and selective manner in tandem with its negative regulators IL-1ra and IL-1RII. Furthermore, we demonstrate that peripheral b2-adrenoceptors mediate the suppression of locomotor activity and food consumption induced by clenbuterol and that these effects are not linked to the central induction of IL-1b. Moreover, despite increasing central IL-1b expression, chronic administration of clenbuterol (0.03 mg/kg; twice daily for 21 days) fails to induce anxiety or depressive-like behaviour in rats in contrast to reports of the ability of exogenously administered IL-1 to induce these symptoms in rodents. Overall, our findings suggest that clenbuterol or other selective b2-adrenoceptor agonists could have the potential to combat neuroinflammatory or neurodegenerative disorders without inducing unwanted symptoms of depression and anxiety.

    Item Type: Article
    Keywords: b2-Adrenoceptor; Clenbuterol; Cytokine; IL-1b; Locomotor activity; Food consumption; Sickness behaviour; Anhedonia; Anxiety; Depression;
    Academic Unit: Faculty of Science and Engineering > Biology
    Item ID: 12569
    Identification Number:
    Depositing User: Eoin McNamee
    Date Deposited: 19 Mar 2020 17:34
    Journal or Publication Title: Brain, Behavior, and Immunity
    Publisher: Elsevier
    Refereed: Yes
    Use Licence: This item is available under a Creative Commons Attribution Non Commercial Share Alike Licence (CC BY-NC-SA). Details of this licence are available here

    Repository Staff Only(login required)

    View Item Item control page


    Downloads per month over past year

    Origin of downloads